

Silvia Montoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3835482/publications.pdf>

Version: 2024-02-01

217
papers

10,260
citations

34100

52
h-index

39667

94
g-index

222
all docs

222
docs citations

222
times ranked

10131
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. <i>Haematologica</i> , 2022, 107, 1054-1063.	3.5	20
2	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	5.2	16
3	The first steps towards a diverse and inclusive EBMT: a position paper. <i>Bone Marrow Transplantation</i> , 2022, 57, 343-346.	2.4	2
4	Follicular lymphoma: life beyond the third line. <i>Lancet Haematology</i> , 2022, 9, e241-e242.	4.6	0
5	Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients. <i>Clinical Infectious Diseases</i> , 2022, 75, 178-179.	5.8	9
6	The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. <i>Leukemia</i> , 2022, 36, 1646-1653.	7.2	6
7	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3541.	2.4	4
8	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party's EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 655-663.	2.4	7
9	Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1391-1401.	2.4	24
10	Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1413-1421.	2.4	9
11	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	1.4	53
12	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , 2021, 8, e205-e215.	4.6	26
13	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	1.6	37
14	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	5.2	24
15	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. <i>European Journal of Cancer</i> , 2021, 157, 132-139.	2.8	4
16	Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party's EBMT. <i>British Journal of Haematology</i> , 2021, , .	2.5	2
17	Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 317-324.	2.4	13
18	Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 393-399.	2.4	29

#	ARTICLE	IF	CITATIONS
19	Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. Bone Marrow Transplantation, 2020, 55, 613-622.	2.4	15
20	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplantation, 2020, 55, 126-136.	2.4	196
21	Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. Bone Marrow Transplantation, 2020, 55, 796-803.	2.4	9
22	Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2020, 55, 633-640.	2.4	5
23	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study. British Journal of Haematology, 2020, 188, 745-756.	2.5	20
24	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. Bone Marrow Transplantation, 2020, 55, 884-890.	2.4	13
25	Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?. Biology of Blood and Marrow Transplantation, 2020, 26, e77-e85.	2.0	41
26	Treatment management of haematological malignancies in people living with HIV. Lancet Haematology, the, 2020, 7, e679-e689.	4.6	18
27	Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Annals of Oncology, 2020, 31, 1251-1259.	1.2	41
28	Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT. Leukemia and Lymphoma, 2020, 61, 2915-2922.	1.3	1
29	Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. Bone Marrow Transplantation, 2020, 55, 2170-2179.	2.4	8
30	Clinical outcome of coronavirus disease 2019 in haematology patients. British Journal of Haematology, 2020, 190, e64-e67.	2.5	81
31	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation, 2020, 55, 2071-2076.	2.4	163
32	Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial. EJHaem, 2020, 1, 133-141.	1.0	5
33	Cellular Therapy in Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 701-714.	2.2	1
34	The investigation and management of follicular lymphoma. British Journal of Haematology, 2020, 191, 363-381.	2.5	14
35	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. Journal of Clinical Oncology, 2020, 38, 1518-1526.	1.6	34
36	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Ts come into focus. Bone Marrow Transplantation, 2020, 55, 1604-1613.	2.4	147

#	ARTICLE	IF	CITATIONS
37	Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. Bone Marrow Transplantation, 2020, 55, 2335-2338.	2.4	3
38	How much has allogeneic stem cell transplantâ€related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Advances, 2020, 4, 6283-6290.	5.2	89
39	Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance. Blood, 2020, 136, 1-2.	1.4	2
40	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. Blood, 2020, 136, 49-50.	1.4	1
41	The Burkitt Lymphoma International Prognostic Index (BL-IPI). Blood, 2020, 136, 46-49.	1.4	0
42	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transplantation, 2019, 54, 44-52.	2.4	59
43	Biosimilar drugs: how safe are they?. Leukemia and Lymphoma, 2019, 60, 3343-3344.	1.3	1
44	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. Bone Marrow Transplantation, 2019, 54, 2060-2071.	2.4	6
45	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematology, the, 2019, 6, e573-e584.	4.6	140
46	Localized FL: how long in response to be cured?. Blood, 2019, 133, 187-188.	1.4	1
47	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 2013-2019.	2.4	21
48	The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. Annals of Hematology, 2019, 98, 1755-1763.	1.8	35
49	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplantation, 2019, 54, 1525-1552.	2.4	218
50	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplantation, 2019, 54, 1575-1585.	2.4	129
51	Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. Bone Marrow Transplantation, 2019, 54, 1625-1631.	2.4	11
52	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. JAMA Oncology, 2019, 5, 715.	7.1	44
53	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Advances, 2019, 3, 360-369.	5.2	92
54	DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT-LWP STUDY. Hematological Oncology, 2019, 37, 316-317.	1.7	0

#	ARTICLE	IF	CITATIONS
55	The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 86-93.	2.0	21
56	Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 562-564.	1.3	1
57	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019, 125, 90-98.	4.1	15
58	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	1.3	6
59	From Ex-Vivo T-Cell Depletion to Post-Transplant Cyclophosphamide: Improved GvHD-Free & Relapse-Free Survival but Comparable Chronic GvHD Incidence in Haploidentical Transplantation. A 15 Years EBMT Registry Analysis on Behalf of the TCWP-EBMT. <i>Blood</i> , 2019, 134, 876-876.	1.4	0
60	The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 43-43.	1.4	0
61	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1001-1009.	2.4	23
62	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. <i>British Journal of Haematology</i> , 2018, 181, 86-96.	2.5	23
63	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , 2018, 5, e190-e200.	4.6	50
64	Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. <i>Leukemia</i> , 2018, 32, 1261-1265.	7.2	87
65	Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2018, 53, 617-624.	2.4	45
66	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. <i>Cancer</i> , 2018, 124, 1733-1742.	4.1	58
67	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1548-1552.	2.4	6
68	Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.	2.5	49
69	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	3.5	90
70	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	2.4	117
71	Treating relapsed follicular lymphoma. <i>Expert Review of Hematology</i> , 2018, 11, 403-410.	2.2	3
72	High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation lymphoma working party. <i>American Journal of Hematology</i> , 2018, 93, 40-46.	4.1	19

#	ARTICLE	IF	CITATIONS
73	Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. <i>Lancet Haematology</i> , 2018, 5, e359-e367.	4.6	74
74	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	2.5	19
75	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2265-2270.	2.0	10
76	Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma. <i>Cancer</i> , 2018, 124, 3455-3456.	4.1	0
77	High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2018, 53, 1553-1559.	2.4	22
78	Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis. <i>Journal of Clinical Oncology</i> , 2018, 36, 7056-7056.	1.6	2
79	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12-years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	1.8	7
80	DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL. <i>Hematological Oncology</i> , 2017, 35, 32-33.	1.7	4
81	High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. <i>Bone Marrow Transplantation</i> , 2017, 52, 1268-1272.	2.4	18
82	Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2017, 52, 1120-1125.	2.4	8
83	Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2017, 52, 811-817.	2.4	310
84	Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience. <i>Bone Marrow Transplantation</i> , 2017, 52, 650-652.	2.4	25
85	Role of stem cell transplant in lymphoma in the era of new drugs. <i>Current Opinion in Oncology</i> , 2017, 29, 455-459.	2.4	10
86	THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA INTO TRANSFORMED-BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE. <i>Hematological Oncology</i> , 2017, 35, 115-116.	1.7	8
87	CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NCRI PHASE II RANDOMISED CHEMO-T TRIAL. <i>Hematological Oncology</i> , 2017, 35, 75-76.	1.7	3
88	BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY. <i>Hematological Oncology</i> , 2017, 35, 83-84.	1.7	0
89	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) FOR PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (R/R SALCL). A RETROSPECTIVE ANALYSIS OF THE LYMPHOMA WORKING PARTY-EBMT. <i>Hematological Oncology</i> , 2017, 35, 242-243.	1.7	0
90	THE ROLE OF 18F FDG-PET/CT IN PERIPHERAL T-CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NCRI MULTICENTRE PHASE II RANDOMISED CHEMO-T TRIAL PET/CT SUBSTUDY. <i>Hematological Oncology</i> , 2017, 35, 244-245.	1.7	0

#	ARTICLE	IF	CITATIONS
91	APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2017, 35, 156-157.	1.7	0
92	CAR-T cells: the narrow path between hope and bankruptcy?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1588-1589.	2.4	24
93	Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 3425-3432.	1.6	132
94	The routes for transformation of follicular lymphoma. <i>Current Opinion in Hematology</i> , 2016, 23, 385-391.	2.5	16
95	Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. <i>Leukemia</i> , 2016, 30, 2086-2089.	7.2	45
96	Reply to the letter to the editor "Survival in young adults diagnosed with follicular lymphoma" by Calvo et al.. <i>Annals of Oncology</i> , 2016, 27, 1173.	1.2	0
97	Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT. <i>Annals of Oncology</i> , 2016, 27, 1088-1094.	1.2	29
98	Recurrent mTORC1-activating RRAC mutations in follicular lymphoma. <i>Nature Genetics</i> , 2016, 48, 183-188.	21.4	160
99	Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial. <i>Blood</i> , 2016, 128, 1855-1855.	1.4	6
100	Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT. <i>Blood</i> , 2016, 128, 4657-4657.	1.4	7
101	Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 4661-4661.	1.4	1
102	Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 514-514.	1.4	1
103	HIV-Associated Hodgkin Lymphoma. , 2016, , 119-132.		1
104	Treatment of patients with transformed lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 625-630.	2.5	15
105	Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. <i>Aids</i> , 2015, 29, 903-910.	2.2	29
106	Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. <i>Cancer</i> , 2015, 121, 423-431.	4.1	34
107	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
108	Life expectancy of young adults with follicular lymphoma. <i>Annals of Oncology</i> , 2015, 26, 2317-2322.	1.2	31

#	ARTICLE	IF	CITATIONS
109	Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone Marrow Transplantation, 2015, 50, 197-203.	2.4	37
110	CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.. Journal of Clinical Oncology, 2015, 33, 8552-8552.	1.6	4
111	Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplantation, 2014, 49, 1360-1365.	2.4	87
112	The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. Annals of Oncology, 2014, 25, 2224-2229.	1.2	23
113	The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma. Nuclear Medicine Communications, 2014, 35, 311-315.	1.1	15
114	Central nervous system prophylaxis in patients with diffuse large B cell lymphoma, are we treating ourselves? A response to the recent BCSH Guideline “ response to Griffin <i>et al</i>. British Journal of Haematology, 2014, 167, 579-580.	2.5	0
115	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics, 2014, 46, 176-181.	21.4	624
116	Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality. Journal of Clinical Oncology, 2014, 32, 273-281.	1.6	133
117	[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. Journal of Clinical Oncology, 2014, 32, 1769-1775.	1.6	149
118	Managing HIV and Hodgkin Lymphoma in the Twenty-first century. Current Hematologic Malignancy Reports, 2014, 9, 227-232.	2.3	5
119	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1729-1736.	2.0	119
120	HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. Aids, 2014, 28, 689-697.	2.2	53
121	Early rituximab failure (ERF) in relapsed diffuse large b-cell lymphoma (DLBCL) and prediction of futility of autologous hematopoietic cell transplantation (AHCT).. Journal of Clinical Oncology, 2014, 32, 7048-7048.	1.6	0
122	A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 1921-1927.	1.3	2
123	Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2013, 19, 746-753.	2.0	83
124	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Annals of Oncology, 2013, 24, 561-576.	1.2	193
125	Hematopoietic Stem Cell Transplantation in Patients with Lymphomatoid Granulomatosis: A European Group for Blood and Marrow Transplantation Report. Biology of Blood and Marrow Transplantation, 2013, 19, 1522-1525.	2.0	15
126	Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2013, 19, 173-179.	2.0	38

#	ARTICLE	IF	CITATIONS
127	Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2013, 19, 1740-1744.	2.0	52
128	EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood, 2013, 122, 3165-3168.	1.4	274
129	The use of interim 18F-fluorodeoxyglucose PET to guide therapy in lymphoma. Future Oncology, 2013, 9, 807-815.	2.4	3
130	The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplantation, 2013, 48, 1409-1414.	2.4	63
131	Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2013, 31, 3100-3109.	1.6	206
132	Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. Haematologica, 2013, 98, 620-625.	3.5	12
133	Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. British Journal of Haematology, 2013, 162, 648-656.	2.5	29
134	Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. British Journal of Haematology, 2013, 163, 168-181.	2.5	50
135	The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood, 2013, 122, 424-433.	1.4	49
136	Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica, 2013, 98, 1014-1021.	3.5	98
137	Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica, 2013, 98, 1762-1768.	3.5	27
138	Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. Journal of Clinical Oncology, 2012, 30, 3848-3853.	1.6	107
139	An innovative joint approach to HIV and lymphoma care. Sexually Transmitted Infections, 2012, 88, 71-71.	1.9	1
140	Management of Localized-Stage Follicular Lymphoma: Changing the Paradigm?. Journal of Clinical Oncology, 2012, 30, 3328-3329.	1.6	6
141	Interim fluoro-2-deoxy-D-glucose PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. Aids, 2012, 26, 861-865.	2.2	18
142	HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. Journal of Clinical Oncology, 2012, 30, 4111-4116.	1.6	145
143	Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR. Biology of Blood and Marrow Transplantation, 2012, 18, 1036-1043.e1.	2.0	15
144	Human immunodeficiency virus-associated plasmablastic lymphoma. Cancer, 2012, 118, 5270-5277.	4.1	147

#	ARTICLE	IF	CITATIONS
145	Guidelines on the investigation and management of follicular lymphoma. British Journal of Haematology, 2012, 156, 446-467.	2.5	58
146	Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis. British Journal of Haematology, 2012, 157, 201-204.	2.5	9
147	CNS Lymphoma in the Immunocompromised Host. , 2012, , 171-179.		0
148	The Clinical Course of Patients with Follicular Lymphoma in the Rituximab Era: A Paradigm Shift. Blood, 2012, 120, 1580-1580.	1.4	1
149	Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project.. Blood, 2012, 120, 2650-2650.	1.4	3
150	Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma. Blood, 2012, 120, 145-145.	1.4	0
151	Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A CIBMTR Analysis. Blood, 2012, 120, 473-473.	1.4	8
152	SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood, 2011, 117, 3147-3150.	1.4	17
153	Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies. British Journal of Haematology, 2011, 154, 448-456.	2.5	20
154	The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia, 2011, 25, 551-555.	7.2	23
155	EZH2 Y641 mutations in follicular lymphoma. Leukemia, 2011, 25, 726-729.	7.2	132
156	Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: A multicenter study. American Journal of Hematology, 2011, 86, 256-261.	4.1	42
157	Transformation of Indolent B-Cell Lymphomas. Journal of Clinical Oncology, 2011, 29, 1827-1834.	1.6	164
158	Use of Zidovudine and Interferon Alfa With Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia/Lymphoma. Journal of Clinical Oncology, 2011, 29, 4696-4701.	1.6	68
159	The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years. Blood, 2011, 118, 1593-1593.	1.4	4
160	A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL). Blood, 2011, 118, 499-499.	1.4	14
161	Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2011, 118, 501-501.	1.4	1
162	T-Cell Lymphomas in South America and Europe. Revista Brasileira De Hematologia E Hemoterapia, 2011, 34, 42-47.	0.7	38

#	ARTICLE	IF	CITATIONS
163	HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era,. Blood, 2011, 118, 3646-3646.	1.4	0
164	HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study. Blood, 2011, 118, 1589-1589.	1.4	1
165	Neither the FLIPI Nor the FLIPI2 Accurately Segregates Low- Risk From Intermediate- Risk Follicular Lymphoma Patients in Terms of Progression-Free Survival. Blood, 2011, 118, 2663-2663.	1.4	0
166	Molecular signatures in the diagnosis and management of follicular lymphoma. Current Opinion in Hematology, 2010, 17, 333-340.	2.5	8
167	Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. Aids, 2010, 24, 851-856.	2.2	54
168	Weekly <i>versus</i> twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. British Journal of Haematology, 2010, 151, 346-353.	2.5	63
169	Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. Haematologica, 2010, 95, 1130-1135.	3.5	10
170	Maintenance rituximab for relapsed follicular lymphoma. Nature Reviews Clinical Oncology, 2010, 7, 677-678.	27.6	1
171	Follicular lymphoma: managing an indolent malignancy. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784314 rgBT /Ove	0.5	0
172	Allogeneic Hematopoietic Cell Transplantation (AHCT) for Primary Cutaneous T Cell Lymphoma (CTCL): a Center for International Blood and Marrow Transplant Research (CIBMTR) Review. Blood, 2010, 116, 364-364.	1.4	3
173	Low dose continuous chemotherapy (LD56): an active treatment with low toxicity for patients with recurrent/refractory lymphoma not eligible for intensive salvage therapy. British Journal of Haematology, 2009, 147, 408-410.	2.5	1
174	Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. British Journal of Haematology, 2009, 147, 719-728.	2.5	40
175	Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood, 2009, 113, 3553-3557.	1.4	129
176	Patterns of Outcome Following Recurrence in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Long Follow-up From a Single Centre.. Blood, 2009, 114, 2921-2921.	1.4	0
177	Follicular lymphomas. Critical Reviews in Oncology/Hematology, 2008, 66, 248-261.	4.4	44
178	Lymphoplasmacytic lymphomaâ€“Waldenström's macroglobulinemia. Critical Reviews in Oncology/Hematology, 2008, 67, 172-185.	4.4	75
179	British HIV Association guidelines for HIVâ€“associated malignancies 2008. HIV Medicine, 2008, 9, 336-388.	2.2	158
180	Oncologic, Endocrine & Metabolic Emerging drugs in B-cell non-Hodgkin's lymphoma. Expert Opinion on Emerging Drugs, 2008, 13, 323-343.	2.4	1

#	ARTICLE	IF	CITATIONS
181	Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood, 2008, 111, 1085-1093.	1.4	107
182	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica, 2008, 93, 207-214.	3.5	24
183	Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Associated Burkitt's Lymphoma (BL). Blood, 2008, 112, 3612-3612.	1.4	0
184	Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma.. Blood, 2008, 112, 3251-3251.	1.4	0
185	Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2007, 25, 2426-2433.	1.6	348
186	Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease. Annals of Internal Medicine, 2007, 147, 836.	3.9	162
187	Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood, 2007, 110, 4132-4133.	1.4	37
188	Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size. Mayo Clinic Proceedings, 2007, 82, 428-434.	3.0	76
189	Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia, 2007, 21, 2324-2331.	7.2	138
190	Rituximab induces long-term remissions in patients with HIV-associated multicentric Castleman's disease. Journal of Clinical Oncology, 2007, 25, 8049-8049.	1.6	0
191	The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Annals of Oncology, 2006, 17, 1539-1545.	1.2	107
192	Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. European Journal of Haematology, 2006, 76, 58-63.	2.2	36
193	Follicular Lymphoma. , 2006, , 348-373.		1
194	Isolated Brain Parenchyma Relapse of Non-Hodgkin's Lymphoma (NHL): A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).. Blood, 2006, 108, 2026-2026.	1.4	2
195	Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Annals of Oncology, 2005, 16, 1508-1513.	1.2	46
196	Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. Journal of Clinical Oncology, 2005, 23, 2797-2804.	1.6	253
197	Bortezomib-Induced Severe Hepatitis in Multiple Myeloma. Archives of Internal Medicine, 2005, 165, 464.	3.8	42
198	Secondary Central Nervous System Lymphoma: Risk Factors and Prophylaxis. Hematology/Oncology Clinics of North America, 2005, 19, 751-763.	2.2	22

#	ARTICLE	IF	CITATIONS
199	Risk and Clinical Implications of Transformation of Follicular Lymphoma (FL) to Diffuse Large Cell B-Cell Lymphoma (tFL).. Blood, 2005, 106, 602-602.	1.4	1
200	Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Annals of Oncology, 2004, 15, 1484-1489.	1.2	66
201	Malignant transformation in IgM monoclonal gammopathy of undetermined significance. Seminars in Oncology, 2003, 30, 178-181.	2.2	17
202	Smoldering multiple myeloma: natural history and recognition of an evolving type. British Journal of Haematology, 2003, 123, 631-636.	2.5	119
203	Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular Lymphoma. Leukemia and Lymphoma, 2003, 44, 71-76.	1.3	37
204	Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Annals of Oncology, 2002, 13, 523-530.	1.2	42
205	Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2002, 117, 387-389.	2.5	7
206	Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab. Annals of Hematology, 2001, 80, 479-481.	1.8	10
207	Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. British Journal of Haematology, 2001, 113, 422-424.	2.5	73
208	Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. British Journal of Haematology, 2001, 115, 575-582.	2.5	222
209	Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer, 2001, 91, 1557-1562.	4.1	22
210	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148.		17
211	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer, 2000, 88, 2142-8.	4.1	5
212	Acute Lymphoid Leukemia Following Polycythemia Vera. Leukemia and Lymphoma, 1999, 32, 395-398.	1.3	11
213	“Lymphoid” blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. British Journal of Haematology, 1998, 100, 129-134.	2.5	79
214	IMPAIRED PRODUCTION OF INTERLEUKIN 6 AND TUMOUR NECROSIS FACTOR γ IN WHOLE BLOOD CELL CULTURES OF PATIENTS WITH MULTIPLE MYELOMA. Cytokine, 1998, 10, 993-996.	3.2	9
215	Renal Failure in Multiple Myeloma. Archives of Internal Medicine, 1998, 158, 1889.	3.8	328
216	Pyoderma Gangrenosum Triggered by γ -Interferon in a Patient with Chronic Granulocytic Leukemia. Leukemia and Lymphoma, 1998, 30, 199-202.	1.3	41

#	ARTICLE	IF	CITATIONS
217	Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. European Journal of Haematology, 1998, 61, 59-64.	2.2	11